AVITA Medical Limited ACN 058 466 523 (Company) is
pleased to confirm that the general meeting to consider a
resolution to approve the proposed scheme of arrangement to effect
a redomiciliation of the Company and its subsidiaries from
Australia to the United States of America (Scheme Meeting)
is being held by way of live webcast
at 9.00am (AEST) on Monday, 15 June 2020 (being 7.00pm (EDT) on
Sunday, 14 June 2020).
The Scheme Booklet prepared in relation to the proposed scheme
of arrangement was despatched (by post or electronically) to
Company shareholders on 14 May 2020. A copy of the Scheme Booklet
can also be found on the Company’s website
(https://avitamedical.com/virtual-shareholders-meeting).
The Notice of Scheme Meeting is contained in Appendix F of the
Scheme Booklet.
Shareholders are reminded that due to the restrictions imposed
by the Australian government in response to the COVID-19 pandemic,
the Scheme Meeting is being held exclusively as a virtual meeting
by way of the live webcast.
Taking part in the live webcast will enable shareholders to
listen to the Scheme Meeting live and view slides and proxy
results. Shareholders who are registered as at 9.00am (AEST) on 13
June 2020 will be entitled to ask questions and cast their vote at
the appropriate times whilst the Scheme Meeting is in progress.
Holders of American Depositary Shares (ADS Holders) are able
to listen to the live webcast, however, will not be able to ask
questions or vote via the live webcast.
The Company will also provide a brief corporate update to
shareholders at the conclusion of the Scheme Meeting.
Shareholders can access the live webcast by following the
instructions below.
Participating in the Scheme Meeting
Shareholders are invited to participate in the Scheme Meeting by
way of the live webcast on two available platforms:
- Web browser - visit https://web.lumiagm.com on your
smartphone, tablet or computer. You will need the latest versions
of Chrome, Safari, Internet Explorer 11, Edge or Firefox; or
- Mobile app - download the Lumi AGM app from the Apple
App Store or Google Play Store by searching for “Lumi AGM”.
Once you have accessed the Lumi platform on your web browser or
mobile device, you will be prompted to enter the meeting ID, which
is: 316-817-384.
Your username is your SRN / HIN (which can be found
towards the top right hand corner of your holding statement and on
shareholder communications).
Your password is the postcode registered to your holding
if you are a shareholder in Australia. If you are a shareholder
outside of Australia, your password is your three letter country
code (for example, “USA” for United States of America). A full list
of country codes is provided in the attached Scheme Meeting User
Guide.
ADS Holders are able to listen to the live webcast of the Scheme
Meeting as a visitor by selecting the ‘guest’ option after entering
the meeting ID.
Further details and instructions on how to participate in the
Scheme Meeting are contained in the Scheme Meeting User Guide, and
on the Company’s website
(https://avitamedical.com/virtual-shareholders-meeting).
Voting by Proxy
Shareholders who are unable to take part in the Scheme Meeting
by way of the live webcast, or choose not to do so, are encouraged
to submit their votes by proxy by no later than 9.00am (AEST) on 13 June 2020. Details on how to
appoint a proxy are set out in section 3.8 of the Scheme
Booklet.
Update details with the Company’s share registry
Shareholders are encouraged to update their details with the
Company’s share registry, Computershare Investor Services Pty Ltd
(Computershare), by accessing Computershare’s website
(www.computershare.com.au/easyupdate/avh) to ensure that payment
instructions are up-to-date in advance of the anticipated
implementation date of the proposed scheme of arrangement.
Authorised for release by the Chief Financial Officer of AVITA
Medical Limited.
ABOUT AVITA MEDICAL LIMITED
AVITA Medical is a regenerative medicine company with a
technology platform positioned to address unmet medical needs in
burns, chronic wounds, and aesthetics indications. AVITA Medical’s
patented and proprietary collection and application technology
provides innovative treatment solutions derived from the
regenerative properties of a patient’s own skin. The medical
devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION,
an autologous suspension comprised of the patient’s skin cells
necessary to regenerate natural healthy epidermis. This autologous
suspension is then sprayed onto the areas of the patient requiring
treatment.
AVITA Medical’s first U.S. product, the RECELL® System, was
approved by the U.S. Food and Drug Administration (FDA) in
September 2018. The RECELL System is indicated for use in the
treatment of acute thermal burns in patients 18 years and older.
The RECELL System is used to prepare Spray-On Skin™ Cells using a
small amount of a patient’s own skin, providing a new way to treat
severe burns, while significantly reducing the amount of donor skin
required. The RECELL System is designed to be used at the point of
care alone or in combination with autografts depending on the depth
of the burn injury. Compelling data from randomized, controlled
clinical trials conducted at major U.S. burn centers and real-world
use in more than 8,000 patients globally, reinforce that the RECELL
System is a significant advancement over the current standard of
care for burn patients and offers benefits in clinical outcomes and
cost savings. Healthcare professionals should read the
INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device
(https://recellsystem.com/) for a full description of indications
for use and important safety information including
contraindications, warnings and precautions.
In international markets, our products are marketed under the
RECELL System brand to promote skin healing in a wide range of
applications including burns, chronic wounds and aesthetics. The
RECELL System is TGA-registered in Australia and received CE-mark
approval in Europe.
To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This announcement includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “intend,” “could,” “may,”
“will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,”
“target,” “project,” “continue,” “outlook,” “guidance,” “future,”
other words of similar meaning and the use of future dates.
Forward-looking statements in this announcement include, but are
not limited to, statements concerning, among other things, our
ongoing clinical trials and product development activities,
regulatory approval of our products, the potential for future
growth in our business, and our ability to achieve our key
strategic, operational and financial goal. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Each forward- looking statement contained in
this announcement is subject to risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statement. Applicable risks and uncertainties
include, among others, the timing of regulatory approvals of our
products; physician acceptance, endorsement, and use of our
products; failure to achieve the anticipated benefits from approval
of our products; the effect of regulatory actions; product
liability claims; risks associated with international operations
and expansion; and other business effects, including the effects of
industry, economic or political conditions outside of the company’s
control. Investors should not place considerable reliance on the
forward-looking statements contained in this announcement.
Investors are encouraged to read our publicly available filings for
a discussion of these and other risks and uncertainties. The
forward-looking statements in this announcement speak only as of
the date of this release, and we undertake no obligation to update
or revise any of these statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200609005857/en/
U.S. Media Sam Brown, Inc. Christy Curran Phone +1
615 414 8668 christycurran@sambrown.com
O.U.S Media Monsoon Communications Rudi Michelson
Phone +61 (0)3 9620 3333 Mobile +61 (0)411 402 737
rudim@monsoon.com.au
Investors: Westwicke Partners Caroline Corner
Phone +1 415 202 5678 caroline.corner@westwicke.com
AVITA Medical Ltd David McIntyre Chief Financial Officer
Phone +1 661 367 9178 dmcintyre@avitamedical.com
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024